Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Equipment
Datasets
Search by expertise, name or affiliation
Tamoxifen - What next?
William J. Gradishar
*
*
Corresponding author for this work
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
36
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tamoxifen - What next?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Tamoxifen
100%
Breast Cancer
62%
Hormone
62%
Endocrine Therapy
50%
Anastrozole
37%
Fulvestrant
37%
Tolerability
25%
Acute Toxicity
25%
Cytotoxic Chemotherapy
25%
Letrozole
25%
Exemestane
25%
Diseases
12%
Disease Exacerbation
12%
Estrogen Receptor Antagonist
12%
Aromatase Inhibitor
12%
Agonist
12%
Hormone Cancer Therapy
12%
INIS
tamoxifen
100%
cancer
62%
therapy
62%
breasts
62%
hormones
50%
patients
25%
diseases
25%
receptors
25%
toxicity
25%
chemotherapy
25%
estrogens
25%
pharmaceuticals
12%
environment
12%
failures
12%
dies
12%